- Home
- TRIB vs BIAF Comparison
TRIB vs BIAF Comparison
Compare TRIB & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- BIAF
- Stock Information
- Founded
- TRIB 1992
- BIAF 2014
- Country
- TRIB Ireland
- BIAF United States
- Employees
- TRIB N/A
- BIAF N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRIB Health Care
- BIAF Health Care
- Exchange
- TRIB Nasdaq
- BIAF Nasdaq
- Market Cap
- TRIB 12.5M
- BIAF 12.2M
- IPO Year
- TRIB N/A
- BIAF 2022
- Fundamental
- Price
- TRIB $0.65
- BIAF $0.28
- Analyst Decision
- TRIB
- BIAF Hold
- Analyst Count
- TRIB 0
- BIAF 1
- Target Price
- TRIB N/A
- BIAF N/A
- AVG Volume (30 Days)
- TRIB 61.0K
- BIAF 9.1M
- Earning Date
- TRIB 06-17-2025
- BIAF 05-15-2025
- Dividend Yield
- TRIB N/A
- BIAF N/A
- EPS Growth
- TRIB N/A
- BIAF N/A
- EPS
- TRIB N/A
- BIAF N/A
- Revenue
- TRIB $61,555,000.00
- BIAF $8,809,228.00
- Revenue This Year
- TRIB $13.51
- BIAF N/A
- Revenue Next Year
- TRIB $13.14
- BIAF $20.00
- P/E Ratio
- TRIB N/A
- BIAF N/A
- Revenue Growth
- TRIB 8.31
- BIAF 78.40
- 52 Week Low
- TRIB $0.48
- BIAF $0.16
- 52 Week High
- TRIB $3.55
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- TRIB 42.17
- BIAF 46.46
- Support Level
- TRIB $0.63
- BIAF $0.24
- Resistance Level
- TRIB $0.68
- BIAF $0.32
- Average True Range (ATR)
- TRIB 0.05
- BIAF 0.06
- MACD
- TRIB -0.01
- BIAF 0.01
- Stochastic Oscillator
- TRIB 7.77
- BIAF 28.07
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.